Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma.
Non-Hodgkin's lymphoma I-131 radioimmunotherapy data were analyzed to determine whether a predictive relationship exists between radiation absorbed doses calculated from biodistribution studies and doses derived from patient size. Radioactivity treatment administrations scaled to patient size (MBq/kg or MBq/m2) or fixed MBq doses do not produce consistent radiation absorbed dose to critical organs. Treatment trials that do not provide dose estimates for critical normal organs are less likely to succeed in identifying a clinical role for radioimmunotherapy.
Eary
J F
JF
University of Washington Medical Center, Department of Radiology, Seattle 98195-6113, USA. jeary@u.washington.edu
Krohn
K A
KA
Press
O W
OW
Durack
L
L
Bernstein
I D
ID
D001830:Body Surface Area; D001835:Body Weight / Q000502:physiology; D006801:Humans; D007457:Iodine Radioisotopes; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy / Q000628:therapy*; D011829:Radiation Dosage; D016499:Radioimmunotherapy / Q000379:methods*; D014018:Tissue Distribution
D007457:Iodine Radioisotopes